Iovance Biotherapeutics News and Activities
Presence
Iovance Biotherapeutics develops cell therapies for cancer treatment. Its products and services include tumor cell therapies, manufacturing support, and clinical development for hospitals, cancer centers, and patients.
Iovance Biotherapeutics products and services overview:
- Cell therapies
- Cancer treatments
- Tissue processing
- Clinical development
- Biomanufacturing services
Revenue: ~$164 million
Employees: 850
Headquarters: San Carlos, United States (USA)
Iovance Biotherapeutics is one of the...
Iovance Biotherapeutics is a company listed under the stock ticker IOVA (US).
Executives
View the org chart displaying its 27 main executives
Most searched biographies at Iovance Biotherapeutics
- Frederick Vogt, Director, Interim Chief Executive Officer, Preside...
- Ryan Maynard, Director
- Wayne Rothbaum, Director
Create your alert
to follow the executive moves at Iovance Biotherapeutics.
Biotechnology
Iovance Biotherapeutics has 2,406 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).
Popular M&A news in Biotechnology
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
- IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
Popular contacts in Biotechnology
News
Press releases by Iovance Biotherapeutics
- Iovance Biotherapeutics to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 4, 2022 | Iovance Biotherapeutics, Inc.
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | Iovance Biotherapeutics, Inc.
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | Iovance Biotherapeutics, Inc.
- Iovance Biotherapeutics Appoints Wendy L. Dixon, Ph.D., to Board of Directors | Iovance Biotherapeutics, Inc.
- Press Releases | Iovance Biotherapeutics, Inc.
- Iovance Biotherapeutics to Present at Upcoming Conferences | Iovance Biotherapeutics, Inc.
- Iovance Biotherapeutics Announces Positive Clinical Data for Lifileucel in Advanced Melanoma | Iovance Biotherapeutics, Inc.
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | Iovance Biotherapeutics, Inc.
- Iovance Biotherapeutics Reports First Quarter 2022 Financial Results and Corporate Updates | Iovance Biotherapeutics, Inc.
- Iovance Biotherapeutics to Present Translational Data for Lifileucel in Advanced Melanoma at 2022 ASCO Annual Meeting | Iovance Biotherapeutics, Inc.
- View more press releases Close
Social media about Iovance Biotherapeutics
- Iovance Biotherapeutics on Wikipedia, Google News & Yahoo Finance
- Iovance Biotherapeutics on LinkedIn, X (Twitter) & YouTube
